Testosterone gel (AndroGel 1.25g)

Phase 3

Testosterone gel (AndroGel 1.25g) is one of 3 therapeutic programs targeting Musculoskeletal Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Musculoskeletal InjuryRecruiting

Musculoskeletal InjuryPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Musculoskeletal Injury

#DrugCompanyPhaseTrials

Zoladex

TTerSera Therapeutics LLC

Approved

1 2

Andriol

AAuxilium

Approved

1 3

Testosterone gel (AndroGel 1.25g)

BBradley Nindl

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

Musculoskeletal Injury

NCT06455969

Clinical

Trials by Indication[1]

Musculoskeletal Injury1 trial

Musculoskeletal Resiliency and Adaptation to Sex Steroid Suppression and Replacement During Multi-Stressor Training

Recruiting·BBradley Nindl·Approved·NCT06455969·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Testosterone gel (AndroGel 1.25g). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Testosterone gel (AndroGel 1.25g). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bradley Nindl company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: BBradley Nindl

Testosterone gel (AndroGel 1.25g)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Musculoskeletal Injury1 trial

References

Drug Info

Quick Facts

Related News